Researchers have identified and studied a new enzyme called BloCAβ from beneficial gut bacteria that works similarly to human enzymes and can be activated by serotonin. According to Gram Research analysis, this enzyme significantly boosted immune cell activity and protected human intestinal cells from inflammation damage in laboratory tests. While this discovery is promising for future probiotic treatments targeting inflammation-related diseases, human clinical trials are still needed before it can be used as a therapy.
Scientists have discovered and studied a special enzyme called BloCAβ that comes from a beneficial bacteria called Bifidobacterium longum, which naturally lives in your gut. According to Gram Research analysis, this enzyme works similarly to enzymes in the human body and may help reduce inflammation caused by oxidative stress. Researchers tested how this enzyme responds to different substances and found that serotonin, a chemical messenger in your body, can activate it and help protect your gut cells. This discovery could lead to new probiotic treatments for diseases linked to an imbalanced gut microbiome and inflammation.
Key Statistics
A 2026 laboratory study published in Archiv der Pharmazie characterized BloCAβ, a new enzyme from Bifidobacterium longum, finding that serotonin activation significantly enhanced metabolic activity in human immune cells under inflammatory conditions.
Researchers found that the bacterial enzyme BloCAβ maintained protective effects on human intestinal cells, preserving their metabolic activity even under inflammatory stress, suggesting potential biocompatibility for probiotic use.
The BloCAβ enzyme displayed catalytic efficiency within the same order of magnitude as human carbonic anhydrase I, indicating it could potentially perform similar biological functions in the gut microbiome.
The Quick Take
- What they studied: How a newly discovered enzyme from good gut bacteria works and whether it can help reduce inflammation in human cells
- Who participated: Laboratory study using human immune cells (macrophages) and intestinal cells grown in dishes, plus comparisons to human enzymes
- Key finding: The bacterial enzyme BloCAβ works similarly to human enzymes and can be activated by serotonin, which helped protect gut cells and boost their activity
- What it means for you: This research is early stage but suggests that engineered probiotics with this enzyme might someday help treat inflammation-related diseases, though human trials are needed first
The Research Details
Researchers created the BloCAβ enzyme in a laboratory using genetic engineering techniques, then purified it to study how it works. They tested the enzyme with various chemical compounds to see which ones could block or activate it, comparing its behavior to similar enzymes found in humans. The team then took this enzyme and tested it on human immune cells and gut cells grown in laboratory dishes to see if it could reduce inflammation and stay safe for human tissue.
This approach allowed scientists to understand the enzyme’s basic properties before testing it in living organisms. By comparing the bacterial enzyme to human versions, they could determine if it might be useful for medical purposes. The safety testing on human gut cells was particularly important because any probiotic treatment would need to be safe for the digestive system.
Understanding how probiotic enzymes work at the molecular level is crucial for developing new treatments. Many diseases involve inflammation and an imbalanced gut microbiome, so finding natural enzymes that can help restore balance could lead to safer alternatives to current medications. This research provides the foundation for future studies that could eventually lead to probiotic-based therapies.
This is a foundational laboratory study that carefully characterized a new enzyme. The researchers used standard scientific methods and compared their findings to well-known human enzymes, which strengthens the reliability of their results. However, because this work was done in laboratory dishes rather than in living people, the findings need confirmation through additional studies before clinical use.
What the Results Show
The BloCAβ enzyme from Bifidobacterium longum functions similarly to a common human enzyme called carbonic anhydrase I, though it works slightly less efficiently. When researchers tested various chemical compounds, they found that serotonin was particularly effective at activating the enzyme and boosting its activity. When this activated enzyme was applied to human immune cells, it significantly increased their metabolic activity, meaning the cells worked better and produced more energy.
The enzyme also protected human intestinal cells from damage, maintaining their metabolic activity even under inflammatory stress conditions. This suggests the enzyme could help protect the gut lining, which is important because a damaged gut lining is linked to many health problems. The researchers tested the enzyme’s safety extensively and found no harmful effects on human intestinal cells, indicating it would be biocompatible if used as a probiotic treatment.
The research tested multiple chemical compounds to understand which ones could inhibit or activate the enzyme, creating a detailed profile of its behavior. Different amino acids and biogenic amines showed varying levels of activation, with serotonin standing out as the most effective. The enzyme responded to compounds in ways similar to human carbonic anhydrase enzymes, suggesting it might fill a similar biological role in the gut.
This is the first detailed biochemical study of this specific bacterial enzyme, so direct comparisons to previous work are limited. However, the enzyme’s behavior aligns with what scientists know about similar enzymes in humans and other bacteria, suggesting the findings are consistent with established enzyme biology. The discovery adds to growing evidence that probiotic bacteria produce enzymes that could have therapeutic value.
This research was conducted entirely in laboratory settings using cells grown in dishes, not in living animals or humans. The sample sizes for cellular experiments were not specified in the published report. The study focused on identifying and characterizing the enzyme rather than testing it as a treatment, so we don’t yet know if it would be effective in actual patients. More research is needed to determine if this enzyme could be safely and effectively used as a probiotic therapy.
The Bottom Line
This research is too early stage for clinical recommendations. It provides important foundational knowledge that scientists will use to develop future probiotic treatments. People interested in gut health should continue following established recommendations: eat fiber-rich foods, consume fermented foods, manage stress, and consult healthcare providers about probiotic supplements.
This research is most relevant to scientists and pharmaceutical companies developing new probiotic treatments. People with inflammatory conditions, digestive issues, or dysbiosis (imbalanced gut bacteria) should be aware that this type of research could eventually lead to new treatment options. However, the findings are not yet ready for public use.
This is basic research, so clinical applications are likely years away. Scientists will need to conduct animal studies, then human clinical trials before any probiotic product based on this enzyme could become available. Realistic timeline is 5 to 10 years minimum before potential therapeutic use.
Frequently Asked Questions
What is BloCAβ and where does it come from?
BloCAβ is a newly discovered enzyme produced by Bifidobacterium longum, a beneficial bacteria naturally found in your gut. Scientists created and studied this enzyme in the laboratory to understand how it works and whether it could help treat inflammation-related diseases.
Can I take a probiotic with this enzyme now?
No, this research is still in early laboratory stages. Scientists have only tested the enzyme in cells grown in dishes, not in living people. Several more years of research, including animal studies and human clinical trials, are needed before any product could become available.
How does serotonin activate this bacterial enzyme?
Researchers found that serotonin, a chemical messenger in your body, can turn on the BloCAβ enzyme and make it work better. When activated this way, the enzyme helped immune cells function more effectively and protected gut cells from inflammation damage.
Could this enzyme help with digestive problems or inflammation?
This research suggests potential future applications for treating inflammation-related diseases and gut imbalance, but it’s too early to say. The enzyme only worked in laboratory cells so far. Much more research is needed before doctors could recommend it for any health condition.
Is this enzyme safe for humans?
Laboratory testing showed no harmful effects on human intestinal cells, suggesting the enzyme would be biocompatible. However, safety testing in living humans hasn’t been done yet. Full safety evaluation requires clinical trials before any therapeutic use.
Want to Apply This Research?
- Track daily probiotic intake and inflammatory symptoms (bloating, digestive discomfort, energy levels) on a 1-10 scale to establish baseline patterns before any new treatments become available
- Users can log current probiotic consumption and note any changes in digestive health or inflammation markers, creating a personal health baseline for future comparison when new probiotic therapies emerge
- Maintain a 12-week log of gut health markers including digestive comfort, energy levels, and inflammation symptoms to track patterns and share with healthcare providers when discussing probiotic options
This research describes laboratory findings about a bacterial enzyme and is not yet ready for clinical application. Do not use this information to self-diagnose or self-treat any condition. If you have concerns about inflammation, digestive health, or dysbiosis, consult with a qualified healthcare provider. Any future probiotic products based on this research would require extensive clinical testing and regulatory approval before becoming available to the public. Current probiotic recommendations should continue to be based on established clinical evidence and guidance from your healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.